Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Onconetix Inc

Healthcare US ONCO

1.03USD
-0.01(0.96%)

Last update at 2026-06-05T20:27:00Z

Day Range

0.921.05
LowHigh

52 Week Range

0.101.58
LowHigh

Fundamentals

  • Previous Close 1.04
  • Market Cap3.66M
  • Volume445987
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-16.37945M
  • Revenue TTM0.76M
  • Revenue Per Share TTM0.04
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -37.42229M -13.41983M -3.41733M -1.59947M -0.82191M
Minority interest - - - - -
Net income -37.40969M -13.41983M -3.41733M -1.59947M -0.82191M
Selling general administrative 14.77M 9.35M 2.09M 1.10M -
Selling and marketing expenses 1.98M - - - -
Gross profit -1.14017M -0.00675M -0.00489M -0.00306M -0.00057M
Reconciled depreciation 0.04M 0.00675M 0.00489M 0.00306M -
Ebit -15.88025M -13.54265M -3.41733M -1.62207M -0.88023M
Ebitda -15.83631M -13.53590M -3.41244M -1.61901M -0.87966M
Depreciation and amortization 0.04M 0.00675M 0.00489M 0.00306M 0.00057M
Non operating income net other - - - - -
Operating income -15.88025M -13.48124M -3.41733M -1.62207M -0.88023M
Other operating expenses 15.94M 13.48M 3.42M 1.62M 0.88M
Interest expense 0.67M 0.00000M - - -
Tax provision -0.01259M 0.00000M - - -
Interest income - - 0.00000M 0.02M 0.06M
Net interest income -0.67163M 0.00000M 0.00000M 0.02M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.01259M -0.06141M -0.00000M - -0.00000M
Total revenue 0.06M 0.00000M 0.00000M 0.00000M -
Total operating expenses 14.74M 13.48M 3.42M 1.62M 0.88M
Cost of revenue 1.20M 0.00675M 0.00489M 0.00306M 0.00057M
Total other income expense net -21.54204M 0.06M -0.00000M 0.02M 0.06M
Discontinued operations - - - - -
Net income from continuing ops -37.40969M -13.41983M -3.41733M -1.59947M -
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 88.82M 26.31M 3.08M 4.81M 6.08M
Intangible assets 25.41M - - - -
Earning assets - - - - -
Other current assets 0.77M 0.47M 0.23M 0.28M 0.00001M
Total liab 23.18M 3.92M 1.64M 0.08M 0.08M
Total stockholder equity 58.63M 22.39M 1.45M 4.73M 6.00M
Deferred long term liab - - - - -
Other current liab 2.20M 2.42M 1.06M - 0.06M
Common stock 0.00023M 0.00016M 0.00003M 0.00003M 0.00001M
Capital stock 0.00023M 0.00016M 0.00004M 0.00004M -
Retained earnings -56.78619M -19.37650M -5.95667M -2.53934M -0.93987M
Other liab - - - - -
Good will 55.68M 0.00000M - - -
Other assets - - - - 0.00000M
Cash 4.55M 25.75M 1.93M 4.31M 6.05M
Cash and equivalents - - - - -
Total current liabilities 17.19M 3.92M 1.64M 0.07M 0.08M
Current deferred revenue - - - - -
Net debt 5.33M -25.75266M -1.92847M -4.30882M -6.05075M
Short term debt 9.69M - - - -
Short long term debt 9.62M - - - -
Short long term debt total 9.89M - - - -
Other stockholder equity 48.80M 41.76M 7.40M 7.27M 6.94M
Property plant equipment - - - - -
Total current assets 5.84M 26.26M 3.07M 4.60M 6.06M
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments - - - - -
Net receivables 0.15M 0.04M 0.15M 0.04M 0.00833M
Long term debt 0.12M - - - -
Inventory 0.36M 0.00000M 0.76M -0.03500M -
Accounts payable 5.30M 1.50M 0.58M 0.07M 0.02M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 2.38M - - - -0.00001M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -25.02735M 0.04M - 0.20M 0.01M
Deferred long term asset charges - - - - -
Non current assets total 82.98M 0.05M 0.01M 0.22M 0.02M
Capital lease obligations 0.15M 0.00000M - - -
Long term debt total - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -8.64903M -0.00934M -0.00192M -0.01179M -
Change to liabilities - - - - -
Total cashflows from investing activities - - - - -
Net borrowings - - - - -
Total cash from financing activities 1.04M 32.53M -0.33419M 0.00000M 6.88M
Change to operating activities - - - - -
Net income -37.40969M -13.41983M -3.41733M -1.59947M -0.82191M
Change in cash -21.19832M 23.82M -2.38035M -1.74193M 6.05M
Begin period cash flow 25.75M 1.93M 4.31M 6.05M -
End period cash flow 4.55M 25.75M 1.93M 4.31M 6.05M
Total cash from operating activities -13.58102M -8.69886M -2.04424M -1.73014M -0.82513M
Issuance of capital stock 2.30M 34.87M 0.00000M 0.00000M -
Depreciation 0.04M 0.00675M 0.00489M 0.00306M 0.00057M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -0.31583M 0.02M 0.11M 0.00147M -
Change to account receivables -0.06229M -0.02333M -0.11496M -0.00147M -0.00833M
Sale purchase of stock -0.05898M -0.56681M 0.00000M - -
Other cashflows from financing activities -0.20509M -1.77202M -0.33419M -0.01179M -0.00450M
Change to netincome - - - - -
Capital expenditures 0.06M 0.00934M 0.00192M 0.01M 0.00450M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.62M 2.54M 1.21M -0.46857M -0.00705M
Stock based compensation 0.33M 1.97M 0.13M 0.33M -
Other non cash items 21.84M 0.26M 0.02M 0.29M -0.00564M
Free cash flow -13.63606M -8.70820M -2.04616M -1.74193M -0.82963M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ONCO
Onconetix Inc		 -0.01 0.96% 1.03 - - 53.53 0.31 -0.4704
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

Onconetix Inc

201 East Fifth Street, Cincinnati, OH, United States, 45202

Key Executives

Name Title Year Born
Dr. Ralph Schiess Ph.D. Interim CEO & Chief Science Officer 1979
Mr. Bruce Harmon Chief Financial Officer 1958
Dr. Brian Price Ph.D. Head of Technology Strategy NA
Mr. Frank A. Jaeger M.A., M.B.A. Senior VP of Marketing & Business Development 1970
Mr. Andrew D. Skibo Ph.D. Global Head of Biologics Operations NA
Mr. Theodore Scott Yoho Head of Business Development NA
Dr. Ali I. Fattom Ph.D. Head of Science & Discovery NA
Dr. Jay Newmark M.B.A., M.D. Chief Medical Officer NA
Mr. Christian Bruhlmann Chief Strategy Officer & GM of Europe 1977
Dr. Donald L. Very Jr., Ph.D. Senior VP of Commercial Research & Development NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.